Overview
Transfusion-Transmitted Cytomegalovirus Prevention in Neonates
Status:
Completed
Completed
Trial end date:
1988-06-01
1988-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate the capacity of intravenously administered cytomegalovirus (CMV)-immune globin (CMVIG) to immunize high risk premature infants against CMV infections.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)Treatments:
Antibodies
Immunoglobulins
Immunoglobulins, Intravenous
Criteria
Neonates at high risk for transfusion-transmitted CMV infection. The neonates were eitherpremature, of low birth weight, or had respiratory distress requiring the presence of an
umbilical catheter.